Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 23
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
6/1/1994
1.
Phase III Randomized, Double-Blind Study of Macrophage Colony-Stimulating Factor vs Placebo, Each with Standard Amphotericin-B Therapy, in Cancer Patients with Definitive or Probable Invasive Candidiasis (Summary Last Modified 06/94)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
3 and over
EORTC-19922
Last Modified:
11/1/1995
2.
Phase III Randomized, Double-Blind Study of Liposomal Amphotericin B vs Standard Formulation Amphotericin B for Empiric Treatment of Persistent Febrile Neutropenia Unresponsive to Broad Spectrum Antibacterial Agents (Summary Last Modified 11/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
2 to 80
NCI
NCI-95-C-0131A
Last Modified:
7/11/2007
3.
Phase III Randomized Study of Liposomal Nystatin vs Standard Amphotericin B for Empiric Treatment of Persistent Febrile Neutropenic Patients (Summary Last Modified 05/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
2 and over
Pharmaceutical / Industry
AR-95-41.356-006
NCI-V96-0845, NCT00002742
Last Modified:
5/14/2007
 
First Published:
7/1/1997
4.
Phase III Randomized Study of Voriconazole vs Amphotericin B in Immunocompromised Patients With Acute Invasive Aspergillosis (Summary Last Modified 01/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
12 and over
Pharmaceutical / Industry
EORTC-19961
PFIZER-150-307-000, NCT00003031
5.
Phase III Study of Chemotherapy with ADR/CCNU/HMM/MTX and Amphotericin B for Advanced non-Small Cell Bronchogenic Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
CHNMC-COH-CA-LUN-1
NCI-D80-035-131
6.
Phase III Empirical Antimicrobial Therapy vs Early Open Lung Biopsy/Specific Therapy for Diffuse Interstitial Pneumonitis in Immunocompromised Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Completed
no age specified
NCI-82-C-111
7.
Phase III Management and Prophylaxis of Fever and Infection with Antimicrobial Treatment in Cancer Patients (Study III)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
no age specified
NCI-81-C-189
NCI-POB-8103
Last Modified:
7/6/2007
8.
Phase III Maintenance Chemotherapy vs TBI/Marrow Transplant Following Conventional Induction and Consolidation for ANLL
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
no age specified
NCI
SWOG-8124/25/26
SWOG-8124, SWOG-8125, SWOG-8126
9.
Phase III Amphotericin-B vs Amphotericin-B/Rifampin for Cancer Patients with Suspected Fungal Infections
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
no age specified
UMCC-7601
10.
Phase III MOX/AMK vs MOX/PIP for Suspected Infection in Febrile, Granulocytopenic Cancer Patients, with Amphotericin-B or Ketoconazole for Failures
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
no age specified
UMCC-8107
Select All on One Page
1
2
3
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute